Open AccessORIENT-32 trial: sintilimab + bevacizumab biosimilar as a promising combination therapy in advanced hepatocellular carcinoma
Author(s) -
Brandon Swed,
Omar Gandarilla,
Gagandeep Brar
Publication year - 2021
Publication title -
digestive medicine research
Language(s) - English
Resource type - Journals
ISSN - 2617-1627
DOI - 10.21037/dmr-21-73
Subject(s) - bevacizumab , biosimilar , hepatocellular carcinoma , medicine , oncology , chemotherapy